• Nenhum resultado encontrado

Compositional Changes of PBL Population in Patients With Chronic Hepatitis B Virus Infection

N/A
N/A
Protected

Academic year: 2019

Share "Compositional Changes of PBL Population in Patients With Chronic Hepatitis B Virus Infection"

Copied!
7
0
0

Texto

(1)

# !'' (!'8

" .( "

3$ $ $ 3$)$$/!

$-$($#$ ), >?>@A

$2- $

$+ $*$++$ +$ , *+$,$ , $+*, $ , % $+,, $-+* # +% $$+-#+ *$ # .9<%6±57%;/%4$* $$ +$ +, + + $$ $#,,&,

+,&,#,,$

,%&$,

$ &,./ 3,.

G

/-2!0

#,%4$$+$ +,+ $# +, +$,$ $,$ ,$# # + *$#

+$-#*% $*, $, ,$,

&,% ,$, *$ $,%

34 "-+*,$ ,- , -#-#-+$ , , %

#/F4 /$!

+$$ $<D 1$ +-%$$% <%4-*C0%$4$4%CH% ! C%07%9DG(! G(G!

L(%-D%-%$$%W$4<%$4%

&$' , !D ( X*H%5-%4%-4$$%$$% 3904-$+--$$/

(!F

* %%&%&'), 9%& &&) '0%' '%&'1*-' .1%,& ) '))%-- %'&2 (),%..%'**.1,, -'%')1%, ,-%(&+, ' O%..%' ,'% %&), -%(&2,,* %%&-%(&D7E%& ''G* ,%+ '-.*-%(&, (&& ( ','%.%-%& & ',* ..(. %' XY2,&,'% %& ,%/,%&0) ,)%,&%&),.%- '+%& &&, 0%.. (%..%'**. , G 2% G7%')%'1%, '%'),& G &G* %&(.&%'- G%'//&) ( .%-%'9(GXY23**J% ..GOWW)%') (.&1%..'&.-,*% G%')%' '/ *&%&'%')%'1%,%))', %&%&2

(2)

!

),'%7 %&X"Y2,&%')..&*&'

%',%'-%'(.%)G.. '! ..%' %'%'/ (")4"4&(**&&%') ,&3&*'&X"Y2

' ** ,&(G%'/,, '%&)7 %('* ,./G %& ' .G& , *,'G*% *&%%' ) *%*, . . .%-!%-.(0G**(. %'&),'% ..G%')* %'& XP+Y2 -%(& ' .G&& ) *%*, . . '(. ..&D;E)* %'&1%,,'% ,* %%&, .'-&% .&(.&XY2 %'-&%/ &'& '%* . '), !..&(&&. &&%',L %X+Y+1, &,&&,1 '%' & '&%/'%)% ', '/&X +Y2'.G+%, &' &,1', '), &'&)&(,%-/'&(.& %&,) , ,'%,* %%&*&'& G' % &%&)%& && &+* %(. .G1,'-%1) *&*%)%(&!,&%' %'&XY2,G, -&,1', '/&%'**(. %'&)%(. %'/.G*,G& ''.G%'* %'&( .&%', .,G %&1, &'-1%,.&&)3/2,&, '/& '&%&) &%',*' /&)αβ

..& ' '%' &%',

'..&

%'/,γδXY2

',%&&(G+1, - ' .G>,*%*, .. .G*,G&DE)%))'* %'&1%,,'% ,* %%&%' ' ')('%))'&''.G%'

L

**(. %'&+ ( .& %' , ..

**(. %'2

! !

(;$7)O* %'&DO .& ') .& 1'G &."G &. ', ') 2O±$E1%,,'%7%')%' '$, .,G %'%-%( .&1%,(7+,* %%&-%(&D7E ' 7%')%'1(&23..* %'&1 % %))',&*% .&%', '+ '+1'PP$! PP"2,&* %'&1&*&%%-)&3/ ' &'/ %-)7 '7+(&%'// ''0'%0 % .0%23..* %'&, 7%')%') . &#',&)&.%'+ %'/,

,&*% .&+ '1 &&%/'%'1/(*& &'3*&%%-'/ %-D .E2,& * %'&, ' . '/)3D 2P±$2"E2

=2$$274.1GG ' .G&%&1 &' ' 4 & ' 1%, 1 .& ) ).(&%' %&,%G ' D4E '*,GG,%'DE!. . '%%& / %'& L

+ L + L + L

+L- '

L3!

bD'%0%'&'E2..&DJE1 ' .G>

(&%'/&)1 D'%0%'&'E2

($$"$")2"7 1* 1%,' . &(9&(&%'/ ' .G&%&%)- % 'D373E2

#

()")&$")$%)!)" 73..* %'& D'_OE(&%',%&&(G1%')1%,7) . &#',& ' ..1&3/*&%%-D .E2 * %'&%'/(*1*&%%-)3/D'_E '&D'_E1'/ %-2 .3/ 1 &&'%',%&/(*2:&%/' ,%&/(*, %('. '*, &)7%')%'2'' &+, 8(*D'_$E+ ..* %'&1*&%%-)3 ' ..1'/ %-)3/DJ** %'&, 13/*&%%-E2

"$"$")/2&!2$$7%' 1,, 'G* %(. %('*,'G*%*)%.& (. &&% 1%,%& &(&+,* %'& *&%%'1* 1%,'., .,G %'%-%( .&2 3& &,1' %' 4%/( + & %&% ..G &%/'%)% '(%'1 &&'%',*' /)

..&D*\2OE &1.. &..&D*\2E%' ..

* %' & * 1%, $ '. &(9&2 ' ' &+ &%/'%)% '%' &%',*' /) ..&D*\2OE1 &&'%')* %'&2

,%))'&1&'%',*' /&), &(&)..&DEC..&D

L

E

'3! 0&1'&%/'%)% '2

(3)

/(*)* %'&24%/(&,1&,%&%(%')

.G*,G&(&&1'1/(*&),'% 7* %'&23&%/'%)% '%' &%'*' /) ..&D*\2E1 &&'%'/(*, -%'/

3b1,'* 1%,/(*D3!E2 3.&+%'/(* &%/'%)% ' &)..&

1 &&-2

4%/( &,1&, ,%' . %'1' %' &)..& ' &)

..&%'

/(* * %'&2 &(, . %' 1 & &' 1'..& '

..&D

'&,1'E2&%/'%)% '%))'&1&' 1' 'G),1/(*&1%,&*..& %'/, %- %' 03!2

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

:, -)(', ,%('*,'G*%*)%.& )* %'&1%))'), .,G'&1%, &%/'%)% ' &%'..&+&*% ..G

..& ' &%/'%)% '%' &%',

..&D4%/(

E2:,',*,'G*%*)%.&),/(*&1 * 1%, ,,+&(,, '/&1

%' '%'/(*, '/(*D4%/(E2,& , '/& G ('),*&' &') 3/ ',-.*')32

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

, '-&% .*&/ %'/

L

%%'* %'&1%,,'%7%')%'2 %'-&%/ &XY&,1%, &%' & 'G,&&,1', '/& ..%'L % XY2 , & ' &,1' , (%'/ G, &'-&%' *, &+ , *' / )

.G*,G&+ *%' '.Gαβ

..&

X+OY &&21-+%)* %'& %'! 3/!'/ %-)#',& ),,* %%&). + &%/'%)% '%' &%'γδ! %'/..&),

(4)

+6%,% . '-%./% ., %&%)* %'&1%,,'%,* %%&-%(& ,%)&.%'

C+6

3;<%$?4$

80

70

60

50

40

30

%C

ell

Normal

Patient

20

10

0

CD3+/CD19- CD3+/CD4+ CD3+/CD8+ CD3-/CD19+ CD3-/CD56/16+ CD3+/HLA-DR+

< . D 3 3 3

4 P b ! ! ; P b ! ! 4 " b ! !

; b ! !

O ; b b ! # ; O b b ! $ ; O b b ! " 4 $ b b ! P 4 O b b b

; $ b b b

4 b ! b

; b ! b

; " b ! b ; " b ! b

O ; b ! b

# 4 OO b ! b $ 4 O b ! b " ; " b ! b P ; $ b ! b

4 b ! b

; O b ! b ; " b ! b

4 O b ! b

; b ! b

(5)

C%6

C)6

70

60

50

40

30

%C

ell

Group I

Group II

20

10

0

CD3+/CD19- CD3+/CD4+ CD3+/CD8+ CD3-/CD19+ CD3-/CD56/16+ CD3+/HLA-DR+

100

0 5 10 15

%CD19

%C

D3

20 25 30 35 40 80

60

40

20

0

(6)

'&(&&2..&1%,γδ*, ('

)WOW)%'' .,( '.+, -'&,1'GJ% / %'& '() /& X#+$Y2:, -&,1', (&),&%/'%)% ' &)

..&,%& %%' &&D2O#%'

' . -&2 2#P %' * %'&E2 : , - &' . %'1',%' &)

..&+

', &)..&%'/(** %'&

1%, 3 *&%%-2 &(, . %' 1 & &-%'/(*1%,3'/ %-, ..&2&&+''.G, %)L%'7 %')%'%&%* '( .&, %)

L

*. G& .%','%7%')%'2

#

8-P-;C&4M%<%$/4$ <%*$ D 1%* 3<%$ #P _$` 4-*%0%$$0$$?4$ $+$%DO0+C566:DG(

)8C4&C3MC%-3<$ <<%- - -*<* <<4-%$ 4 $%$<%$ /4$?%-;<%$566; D(G

1%$8CH7C3:$)C%-4H(-< -- $<$ <%$ % <%$ D % % % %/% $ 4 $<$ <%$ /4$C ;<%-*

566= D (G

#(&&CL-%$$LC;%$-PCL$$91 % --$ * <%$ /4$ &%56;< DF(

L-%$$LC#(&&CL$$91C%-L/ 9%$%-$<%$/%-K+ %%4-4%%<%-* <%$/4$0K%-+%)N)+

56;8 D!(

! &(&LC%-%$%%1C&<538C;% +# ;<%$ /4$ K+ -/ % - --$ <%$ <%% K+

56;< D(

F ]CK%3+C1-:&C;--7 ;<%$ /4$ K+ 4-% --$ % %%-*$$$4$$<$<-%/ % $ / % - K + $

56;: GD F(F

K%%%4[CK%:)#CK%:)74%-<-%$ <%$$4%%;$+H--$ ;?%$?%-;<%$5667 D(

G 34 3(1C &-% ](7 0<%- H(-- $4$$

%$*<%<%$(/4$%$3--4-56;: GD(F

$%&4-%$$/%-<%$D?*%$8KC$%&C;%-; _$`?%- ;<%$ % &/ $%$ K]:D 84=)%C56;8D(!!

H%$;3CC#48C%-4% $4<<$$ H --$ <%$ /4$ 4 -/ $%$;<%-*56;9 D(

+-9% 8&1C 1-- 1C K%4/ K?C %74% %%5% <<% --*<*$ ;$+ %$ 3- L9< 4-56;: !D G(F

#$ 78C #% )HC 0-- #0 44-%*H--$$4$$<%$ /4$ D -4 $94%-* ;<%-*56;< DG(

#%*$8C8C?%<41)4<<$$--4-/$%$&%56;< D

1-#C31C)a-7C%-#---$ %<$%<%$0K%-+%)N)+5667 G D !(

! 3%3CL$8C)<-#C%-L9<$$ <%%/%<%$/4$$ 64 / % < % ?

-56;7 !D

F )-;C)%-C)%--;H<(34: <%$/4$$%$%-$64$ $$%-$*$$%$<$$ <%$ 4 /4$ %

?-56;7 !DF

1-#C31C)-7C%-#---$ %<$%<%$<K%-+%)N)+5667 G D !

G 1-#C$C;4$C1%4*%%H#-H -- -% <$$ <%$ /4$ 4566< D!

$ <%$ % 4 4--%4j0K%-+%) N)+566@ FD!GG

H%$ ;3C 1 C P% C 1% ?4$($ %<%$/4$) &/$56;; D

1-#C31[C;4$&C$LH $ <%$ < % % 4-% 4 $<$ 4-%<$D % %$ <$$

4-566; !D(

1%4*%%HC1&%-%+C&)C%-H$-* <%$/$3-/$

(7)

41(3C)%4PC)%%HC%-%$

64*3d3 #Od*H-*<*$ %4 <%$ /4$

;<%-566< DG(

K:-<4-4?C):4-$+CH<4-$[C%-+ %$ 4 4-%γδ H3#d --$ <%$/%-<%$7L1)4-11-566= D(

! )4LC%%:%LC7$0C%-;4%?γG?δH -- <(?γδ -*<*$ $ $<* %4 4: -*<% --$

4-566@ D(

Referências

Documentos relacionados

related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Cofactor dependence and isotype

We assessed occult HBV infection prevalence in two groups of immunocompromised patients (maintenance hemodialysis patients and HIV-positive patients) presenting HBsAg- negative

Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. Evaluation and comparison of different

O Brasil enfrentou diversas crises financeiras, sofrendo com a escassez de dólares no balanço de pagamentos em diversos momentos de sua história recente, como na moratória da

Such contradiction in the process of nursing training, associated to the increase in chronic degenerative diseases, due to the increase in fostered human sur- vival,

Infection with hepatitis C virus (HCV) affects millions of individuals in the world, resulting in chronic liver disease like chronic hepatitis (CH) and hepatocellular carcinoma

Sei que a maior responsabilidade é dele, mas gostaria de saber se como analista de um sistema, você deve fazer toda a análise de requisitos do projeto ou se existe algum setor da

Seroepidemiology of hepatitis A virus infection among school children in Delhi and north Indian patients with chronic liver disease: implications for HAV vaccination. Ferreira CT,